RAMI MANOCHAKIAN MD NPI 1619112034

NPI Details

Rami Manochakian, MD is a hematology and oncology internal medicine in Jacksonville, FL with 22 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Rami Manochakian, MD NPI is 1619112034. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

4500 SAN PABLO RD S
JACKSONVILLE, FL
ZIP 32224-865
Phone: (904) 953-2000

The NPI 1619112034 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg (HCPCS:Q5118)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, trastuzumab-qyyp, biosimilar, (trazimera), 10 mg (HCPCS:Q5116)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Collection of blood sample from implanted device (HCPCS:36591)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection of drug or substance into vein (HCPCS:96374)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)

The enumeration date for this NPI number is 12/15/2008 and was last updated on 8/31/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: